Valuation: Cardiol Therapeutics Inc.

Market Cap 187M 132M 117M 109M 99.05M 12.54B 190M 1.31B 513M 6.54B 496M 485M 20.86B P/E 2026 *
-3.33x
P/E 2027 * -5.45x
Enterprise Value 168M 119M 105M 97.77M 88.96M 11.26B 171M 1.18B 461M 5.88B 445M 436M 18.74B EV / Sales 2026 *
-
EV / Sales 2027 * 108x
Free-Float
97.73%
Yield 2026 *
-
Yield 2027 * -
09-23 Cardiol Therapeutics Achieves Phase III Maveric Enrollment Target Ahead of Schedule and Expands Pivotal Trial CI
09-23 Cardiol Therapeutics Inc. Achieves MAVERIC Enrollment Target And Expands Pivotal Trial Evaluating CardiolRx CI
08-12 Cardiol Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
05-11 Cardiol Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
05-07 Cardiol Adds Results "Further Validate" Ongoing Phase III Trial, Which Recently Surpassed 75% Enrollment MT
05-07 Cardiol Says Results Demonstrate CardiolRx "May Represent a Paradigm Shift" In the Treatment of Patients With Recurrent Pericarditis MT
05-07 Cardiol Therapeutics Says Its Phase II MAvERIC Results Accepted For Publication In The Journal Of The American Heart Association MT
05-07 Cardiol Therapeutics Inc Announces Phase II Maveric Results Accepted for Publication in the Journal of the American Heart Association CI
04-28 Cardiol Therapeutics Up In US Premarket As Expands Phase 3 Maveric Trial to Include 7 More Clinical Centers in the U.S. MT
04-28 Cardiol Therapeutics Inc. Expands Maveric Phase III Trial Network and Provides Clinical Updates on Cardiolrx CI
04-01 Cardiol Therapeutics Fiscal 2025 Loss Narrows; Says Now Fully Funded Through Completion of MAVERIC trial MT
04-01 Cardiol Therapeutics initiated pivotal Phase III Maveric trial of Cardiolrx in recurrent pericarditis RE
04-01 Cardiol Therapeutics Inc. Provides Update on Strategic Priorities CI
1 day-2.50%
1 week-12.36%
Current month-34.18%
1 month-40.46%
3 months-10.34%
6 months-18.32%
Current year+19.08%
1 week 1.54
Extreme 1.54
1.76
1 month 1.54
Extreme 1.54
2.78
Current year 1.22
Extreme 1.225
3.23
1 year 1.22
Extreme 1.225
3.23
3 years 0.91
Extreme 0.91
4.26
5 years 0.61
Extreme 0.61
6.11
10 years 0.61
Extreme 0.61
8.49
Manager TitleAgeSince
Chief Executive Officer - 2017-01-18
Director of Finance/CFO - 2018-08-15
Chief Operating Officer - 2020-12-02
Director TitleAgeSince
Director/Board Member - 2017-12-14
Director/Board Member - 2017-01-18
Chairman - 2021-07-06
Date Insider Type Main position Quantity % Market Cap. Importance
9/8/26 Option

Chairman

25,000 0.0214%
9/8/26 Option

Chairman

-25,000 0.0214%
8/28/26 Option

Chief Technology Officer

-70,000 0.0599%
Change 5-day change 1-year change 3-year change Capi.($)
-1.88%-12.36%+6.85%+41.82% 132M
-6.60%-10.93%+45.08%+60.01% 68.98B
-4.09%-0.11%+2.31%+54.81% 53.15B
+0.03%+5.56%+10.18%+41.75% 50.83B
-2.27%+2.37%+29.30%+33.70% 44.61B
-5.93%-6.04%+258.91%+422.58% 40.57B
-1.39%+3.82%+15.72%+111.57% 42.53B
+6.53%+8.02%+18.98%+54.58% 30.95B
-0.90%-10.91%+34.11%-1.83% 25.44B
-2.44%-9.40%-16.40%-9.40% 22.66B
Average -2.00%+0.02%+40.50%+80.96% 37.99B
Weighted average by Cap. -2.55%+1.65%+45.58%+89.51%

Financials

2026 *2027 *
Net sales - 1.67M 1.18M 1.05M 971K 883K 112M 1.69M 11.67M 4.58M 58.35M 4.42M 4.33M 186M
Net income -36.11M -25.52M -22.69M -21.03M -19.13M -2.42B -36.68M -253M -99.11M -1.26B -95.79M -93.75M -4.03B -37.94M -26.82M -23.84M -22.1M -20.11M -2.55B -38.55M -266M -104M -1.33B -101M -98.52M -4.23B
Net Debt -19.05M -13.47M -11.97M -11.1M -10.1M -1.28B -19.36M -133M -52.3M -667M -50.55M -49.47M -2.13B -6.59M -4.66M -4.14M -3.84M -3.49M -442M -6.7M -46.17M -18.1M -231M -17.5M -17.12M -736M
Projected Income Statement - Annual - Cardiol Therapeutics Inc.
Logo Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc. is a Canada-based clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small-molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It holds investigational new drug application authorization from the United States Food and Drug Administration (US FDA) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The Company is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure.
Employees
18
Date Price Change Volume
26-10-16 $1.570 -1.88% 81,020
26-10-15 $1.600 0.00% 279,428
26-10-14 $1.600 -6.43% 158,351
26-10-13 $1.710 -3.93% 217,553
26-10-09 $1.780 -3.78% 179,622
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Cardiol Therapeutics Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.600CAD
Average target price
7.000CAD
Spread / Average Target
+337.50%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Cardiol Therapeutics Inc.
  1. Stock Market
  2. Stocks
  3. CRDL Stock